Decision Benefits Medicaid Patients with Chronic Wounds

NEWPORT NEWS, Virginia (January 1, 2014) – Effective immediately, MassHealth, the Massachusetts Medicaid Agency, will provide coverage for the use of TheraSkin®, a real skin therapy that effectively treats chronic wounds. This decision is consistent with MassHealth’s history of supporting innovative and cost effective healthcare solutions for the people of Massachusetts.

“We applaud the decision by MassHealth to cover this limb and life-saving product,” said Kerry McCarter, CEO of Soluble Systems, LLC, the parent company of TheraSkin, explaining that Massachusetts residents with diabetic and venous leg ulcers will now have access to cost-effective living cell therapy. Living cell therapy has been cited as the new standard of care for these ulcers.

Patients who have particularly benefited from the wound healing capabilities of TheraSkin are those with diabetes. “Diabetics are likely to develop foot ulcers, which are often extremely difficult to heal,” explained McCarter. “When all else fails, these patients are involved in nearly two-thirds of all non-traumatic lower limb amputations each year. In Massachusetts, 38 lower leg amputations every week are due to diabetes.” TheraSkin clinical results demonstrate the potential to save many patients from these life-threatening lower limb amputations by effectively closing over 60% of previously “non-healing” diabetic and venous ulcers in 12 weeks.

About 19% adults in Massachusetts over 65 have been told they have Type 2 diabetes. The number of residents with Type 2 diabetes has more than doubled in the last ten years. “We will work tirelessly with the medical institutions and practitioners in Massachusetts to help implement the clinical and economic benefits of TheraSkin,” said Allan Staley, President of Soluble Systems.

TheraSkin is not only clinically effective, but economical, costing 50 – 70% less than competing biologically active products, saving patients and payers thousands of dollars per treatment. A potent new weapon in the battle against rising healthcare costs, TheraSkin has the potential to save patients and the U.S. healthcare system more than $1 billion over the next decade.

TheraSkin is a biologically active cryo-preserved human skin allograft for non-responsive chronic wounds. Its fully developed extracellular matrix (ECM) and living cells provide an “at-ready” supply of human growth factors, cytokines and collagen to jumpstart wound healing.

Like competing biologically active skin substitutes, TheraSkin provides necessary growth factors and cytokines to treat chronic wounds; however, it also provides a large quantity of essential human collagens in appropriate ratios to support healing. This allows TheraSkin to be used on more severe wounds with exposed bone, tendon, joint capsules or muscle.